MPE gives feedback on the proposed implementing act supporting the EU Health Technology Assessment regulationAccess, MPE8 April 2024
European Commission grants final approval for CAR-T treatment idecabtagene vicleucel (Abecma) in earlier lines of therapy for relapsed and refractory myelomaAccess, Myeloma21 March 2024
EMA CHMP gives positive recommendation on CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myelomaAccess, Myeloma23 February 2024
US FDA approves bi-weekly teclistamab dosing in relapsed/refractory myelomaAccess, MPE, Myeloma22 February 2024
AMEN provides medical information for Arabic speakers in Israel and beyondAccess, MPE13 February 2024
EMA CHMP gives positive opinion on CAR-T treatment idecabtagene vicleucel (Abecma) in earlier lines of therapy for relapsed and refractory myelomaAccess, Myeloma30 January 2024
EMA CHMP confirms recommendation for non-renewal of Blenrep marketing authorisationAccess, MPE15 December 2023
The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory myelomaAccess, Myeloma8 December 2023
MPE launches European Amyloidosis Diagnosis Pathway to promote early detection of the rare diseaseAccess, AL amyloidosis26 October 2023
